New drug tested for rare energy disorder

NCT ID NCT05972954

Summary

This study tested an experimental drug called OMT-28 for people with primary mitochondrial disease, a rare condition where the body's energy-producing cells don't work properly. Researchers gave 28 patients the daily medication for 6 months to check if it was safe, reduced certain blood markers of disease, and helped with symptoms like fatigue. They compared results from the treatment period to a prior 3-month period when patients received only standard care.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRIMARY MITOCHONDRIAL DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Azienda Ospedaliero Universitaria Pisana, P.O. Santa Chiara, U.O. Neurologia, Edificio 13, Via Roma 67

    Pisa, 56126, Italy

  • Friedrich-Baur-Institut an der Neurologischen Klinik und Poliklinik, Klinikum der Universität München, Ludwig-Maximilians-Universität (LMU Klinikum), Ziemssenstr. 1a

    Munich, 80336, Germany

  • IRCCS Institute of Neurological Science of Bologna, University of Bologna, Department of Biomedical and Neuromotor Science (DIBINEM), Ospedale Bellaria Via Altura, 3

    Bologna, 40139, Italy

  • IRCCS Istituto Neurologico Carlo Besta, SC Servizio Di Medicina Di Laboratorio - Genetica Medica E Neurogenetica, Via Celoria 11

    Milan, 20133, Italy

  • Medizinisch Fakultät der Martin-Luther-Universität Halle-Wittenberg Universitätsklinik und Poliklinik für Neurologie Universitätsklinikum , Ernst-Grube-Str. 40

    Halle, 06120, Germany

  • Radboud University Nijmegen Medical Centre

    Nijmegen, Gelderland, 6500 HB, Netherlands

  • U.O.C. di Neurologia e Malattie Neuromuscolari

    Messina, 98125, Italy

  • UOC di neurofisiopatologia

    Roma, 8-00168, Italy

  • Universitätsklinikum Bonn, Sektion Neuromuskuläre Erkrankungen, Klinik und Poliklinik für Neurologie, Venusberg-Campus 1, Gebäude 80, NPP

    Bonn, 53127, Germany

Conditions

Explore the condition pages connected to this study.